----
Current ValuationThe current P/E ratio is -3.33, within the reasonable range, cheaper than 35.74% of the time in the past 5 years, and the industry ranks 149/256, the industry Median -1.14.
-3.33xP/E
$3.42Stock price
$-1.03Earnings per share
-3.33xP/E
Stock price$3.42Earnings per share$-1.03
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -6.42x
- Typical range
- -11.90x–-2.32x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0295887116
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
TAKUSTakeda Pharmaceutical Company | -60.73x | 154.63% | $63.44B |
BAYZFUSBayer Aktiengesellschaft | -24.08x | -- | $48.51B |
BAYRYUSBayer | -23.82x | -- | $47.98B |
VTRSUSViatris | -52.16x | 107.68% | $21.42B |
ELANUSElanco Animal Health | -56.99x | 129.36% | $11.34B |
VREOFUSVIREO GROWTH INC | -126.24x | -- | $8.47B |
AXSMUSAxsome Therap | -43.62x | 21.51% | $8.36B |
BLTEUSBelite Bio | -60.76x | 29.87% | $6.22B |
CURLFUSCuraleaf Holdings, Inc. | -115.64x | -- | $6.02B |
MANEUSVeraDermics | -50.92x | 97.44% | $5.31B |
RGCUSRegencell Bioscience | -442.47x | -- | $5.18B |
DFTXUSDefinium Therapeutics | -13.33x | 54.55% | $4.71B |
EWTXUSEdgewise Therapeutics | -21.89x | 207.38% | $4.32B |
AMLXUSAmylyx Pharmaceuticals | -23.74x | 1.76% | $3.61B |
TARSUSTarsus Pharmaceuticals | -67.07x | 201.10% | $3.12B |
ELVNUSEnliven Therapeutics | -28.53x | 5.59% | $3.02B |
MBXUSMBX Biosciences | -24.71x | 31.12% | $2.58B |
BHCUSBausch Health | -2.19x | 569.84% | $2.40B |
SUPNUSSupernus Pharma | -21.81x | 66.18% | $2.40B |
PRGOUSPerrigo | -1.29x | 100.10% | $2.24B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
